- Home
- YXT vs NKTR Comparison
YXT vs NKTR Comparison
Compare YXT & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- NKTR
- Stock Information
- Founded
- YXT 2011
- NKTR 1990
- Country
- YXT China
- NKTR United States
- Employees
- YXT N/A
- NKTR N/A
- Industry
- YXT
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- NKTR Health Care
- Exchange
- YXT NYSE
- NKTR Nasdaq
- Market Cap
- YXT 268.5M
- NKTR 247.9M
- IPO Year
- YXT 2024
- NKTR 1994
- Fundamental
- Price
- YXT $2.15
- NKTR $1.40
- Analyst Decision
- YXT
- NKTR Buy
- Analyst Count
- YXT 0
- NKTR 5
- Target Price
- YXT N/A
- NKTR $4.00
- AVG Volume (30 Days)
- YXT 20.9K
- NKTR 1.7M
- Earning Date
- YXT 11-21-2024
- NKTR 11-07-2024
- Dividend Yield
- YXT N/A
- NKTR N/A
- EPS Growth
- YXT N/A
- NKTR N/A
- EPS
- YXT N/A
- NKTR N/A
- Revenue
- YXT $53,329,409.00
- NKTR $93,137,000.00
- Revenue This Year
- YXT N/A
- NKTR N/A
- Revenue Next Year
- YXT N/A
- NKTR N/A
- P/E Ratio
- YXT N/A
- NKTR N/A
- Revenue Growth
- YXT N/A
- NKTR 5.53
- 52 Week Low
- YXT $2.05
- NKTR $0.41
- 52 Week High
- YXT $11.00
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- NKTR 56.35
- Support Level
- YXT N/A
- NKTR $1.33
- Resistance Level
- YXT N/A
- NKTR $1.47
- Average True Range (ATR)
- YXT 0.00
- NKTR 0.09
- MACD
- YXT 0.00
- NKTR 0.00
- Stochastic Oscillator
- YXT 0.00
- NKTR 75.00
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.